Compare Rigetti Computing Inc (RGTI) vs Summit Therapeutics Inc (SMMT) Price & Performance

Rigetti Computing (RGTI) trades at $14.25, up 0.99% on the day, while showing bearish technical signals with 17 sell indicators versus 5 buy signals. The company maintains strong analyst support with 85.7% buy ratings and a $32.67 consensus price target, despite posting significant losses (-$216.21M net income) and negative margins. Recent news highlights Rigetti's $569M cash position and government contracts supporting its quantum computing roadmap.

RGTI offers substantial upside potential based on analyst targets but carries high risk due to persistent losses and negative profitability metrics. The stock's investment thesis hinges on successful quantum technology commercialization, with current valuation reflecting speculative growth expectations rather than fundamental performance.

Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.

The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.